ASP-7317 is under clinical development by Astellas Pharma and currently in Phase II for Juvenile Macular Degeneration (Stargardt Disease). According to GlobalData, Phase II drugs for Juvenile Macular Degeneration (Stargardt Disease) does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the ASP-7317 LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
ASP-7317 overview
ASP-7317 (Retinal pigment epithelial cell program, MA09-hRPE) is under development for the treatment of Stargardt disease (juvenile macular degeneration) and geographic atrophy associated with dry age-related macular degeneration (dry AMD). RPE cells are administered as subretinal injections. Retinal pigment epithelial cells are derived from human embryonic stem cells (hESCs). The program is based on advanced cell technology. It was also under development for the treatment of myopic macular degeneration.
Astellas Pharma overview
Astellas Pharma (Astellas) discovers, develops, manufactures, and commercializes a wide range of pharmaceuticals. The company’s product portfolio comprises marketed products for the treatment of a wide range of urological diseases, cancer, nephrology, infectious diseases, and metabolic diseases, immunodeficiency, and transplantation. The company strives to develop new drugs to address high unmet medical needs with focus on biology and modality. Its pipeline consists of drug candidates for the treatment of urothelial cancer; gastric cancer; gastroesophageal junction cancer; anemia associated with chronic kidney disease (CKD) in dialysis; and acute myeloid leukemia (AML), among others. It operates in the Americas, Australia, Europe, and Asia and Oceania through a network of subsidiaries and affiliates. Astellas is headquartered in Chuo-Ku, Tokyo, Japan.
For a complete picture of ASP-7317’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
